Eye­ing one of the first RNAi ther­a­pies and cho­les­terol block­buster, Med­Co shows de­tailed in­clisir­an da­ta

The main ques­tion was not whether it would work; it was if it would be safe.

The Med­i­cines Com­pa­ny is out with new da­ta on its LDL cho­les­terol drug in­clisir­an, and they con­firm the first, ten­ta­tive an­swers: Yes. They al­so keep Med­Co on track for an im­mi­nent  FDA sub­mis­sion for one of the first RNAi ther­a­pies and a drug that could flip the cho­les­terol mar­ket. An EU ap­pli­ca­tion will fol­low in the first quar­ter of 2020.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.